These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 37498367)

  • 1. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.
    Andreasen CR; Andersen A; Vilsbøll T
    Diabetologia; 2023 Oct; 66(10):1846-1858. PubMed ID: 37498367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.
    Targher G; Mantovani A; Byrne CD
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):179-191. PubMed ID: 36620987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-mediated control of cardiac energy metabolism.
    Chan JSF; Shafaati T; Ussher JR
    J Endocrinol; 2024 Oct; 263(1):. PubMed ID: 39013412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on peptide-based therapies for type 2 diabetes and obesity.
    Bailey CJ; Flatt PR; Conlon JM
    Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of dual incretin receptor agonism by tirzepatide.
    Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW
    Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in peptide-based therapies for obesity and type 2 diabetes.
    Bailey CJ; Flatt PR; Conlon JM
    Peptides; 2024 Mar; 173():171149. PubMed ID: 38184193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity pharmacotherapy: incretin action in the central nervous system.
    Boer GA; Hay DL; Tups A
    Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
    Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z
    J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
    Novikoff A; Müller TD
    Physiology (Bethesda); 2024 May; 39(3):142-156. PubMed ID: 38353610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of peptides used for the treatment of diabetes/obesity: A personal journey.
    Marks V
    Peptides; 2023 Dec; 170():171115. PubMed ID: 37924847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incretin as a Novel Treatment Strategy for NAFLD/NASH].
    Takeda Y; Ikeda R; Kondo T
    Yakugaku Zasshi; 2016; 136(4):573-7. PubMed ID: 27040341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.